Kiribati
Tuberculosis profile
Population  2013 <1 million
Estimates of TB burden * 2013 Number (thousands) Rate
(per 100 000 population)
Mortality (excludes HIV+TB) 0.03 (0.024–0.036) 29 (23–35)
Mortality (HIV+TB only) 0 (–) 0 (–)
Prevalence  (includes HIV+TB) 0.77 (0.36–1.3) 748 (352–1 290)
Incidence  (includes HIV+TB) 0.51 (0.41–0.61) 497 (404–599)
Incidence (HIV+TB only)        
Case detection, all forms (%) 80 (66–98)    
Estimates of MDR-TB burden * 2013   New   Retreatment
% of TB cases with MDR-TB 4.5 (2.7–6.4) 24 (20–27)
MDR-TB cases among notified pulmonary
TB cases
13 (8–18) 11 (9–12)
TB case notifications 2013 New ** Relapse
Pulmonary, bacteriologically confirmed 128   22
Pulmonary, clinically diagnosed 159   10
Extrapulmonary 85   3
       
Total new and relapse 407    
Previously treated, excluding relapses 13    
Total cases notified 420    
Among 410 new and relapse cases:
95 (23%) cases aged under 15 years; male:female ratio: 1.1
Reported cases of RR-/MDR-TB 2013 New Retreatment Total **
Cases tested for RR-/MDR-TB 0 (0%) 0 (0%) 0
Laboratory-confirmed RR-/MDR-TB cases     0
Patients started on MDR-TB treatment     0
TB/HIV 2013 Number (%)
TB patients with known HIV status 274 (65)
HIV-positive TB patients 0 (0)
HIV-positive TB patients on co-trimoxazole preventive therapy (CPT) 0  
HIV-positive TB patients on antiretroviral therapy (ART) 0  
HIV-positive people screened for TB    
HIV-positive people provided with IPT    
Treatment success rate (%)
New and relapse cases registered in 2012 89
Previously treated cases, excluding relapse, registered in 2012 85
HIV-positive TB cases, all types, registered in 2012  
RR-/MDR-TB cases started on second-line treatment in 2011  
XDR-TB cases started on second-line treatment in 2011  
Laboratories 2013  
Smear (per 100 000 population) 2.0
Culture (per 5 million population) 48.9
Drug susceptibility testing (per 5 million population) 0
Sites performing Xpert MTB/RIF 0
Is second-line drug susceptibility testing available? Yes, outside
country
Financing TB control 2014  
National TB programme budget (US$ millions) <1
% Funded domestically  
% Funded internationally 75%
% Unfunded 25%
* Ranges represent uncertainty intervals
** Includes cases with unknown previous TB treatment history
***
(Rate per 100 000 population per year)
Mortality graph
   Mortality  (excludes HIV+TB)

(Rate per 100 000 population)
Prevalence graph
   Prevalence

(Rate per 100 000 population per year)
Incidence graph
   Notified (new and relapse)   Incidence
   Incidence (HIV+TB only)

(Number of patients)
CPT ART graph
   HIV-positive TB patients
   on CPT   on ART

Treatment success rate (%)
tx success graph
   New   Retreatment
   New and relapse   Retreatment, excluding
relapse
   HIV-positive   RR-/MDR-TB   XDR-TB

Total budget (US$ millions)
Budget funding Graph
__Funded domestically__Funded internationally
__Unfunded
 
 Data are as reported to WHO. Estimates of TB and MDR-TB burden are produced by WHO in consultation with countries.
 Generated: 2015-07-03 Data: www.who.int/tb/data